Safety

OMNIA Protocol Integrates Blockpass to Secure DeFi Trading

Source Node:
Time Stamp: April 2, 2024 12:12 PM - Modified On: April 2, 2024 - Published By:
Source Cluster:
Republished By Plato

HONG KONG, Apr 2, 2024 - (ACN Newswire) - Blockpass is pleased to reveal a new partnership as OMNIA Protocol, a specialized RPC provider for DeFi traders, integrates Blockpass’ regulatory regulatory solutions. Through this integration, OMNIA benefits from compliance measures that include KYC, AML and KYB that will protect its users as they utilize the benefits of DeFi and the crypto space. Created by cybersecurity, privacy and trading experts, OMNIA aims to tackle DeFi issues including front-running and MEV exploitation to create an ecosystem where anyone can enjoy an unparalleled

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:49 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

[Mirror] A Proof of Stake Design Philosophy

Source Node:
Time Stamp: February 2, 2024 10:55 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/a-proof-of-stake-design-philosophy-506585978d51 Systems like Ethereum (and Bitcoin, and NXT, and Bitshares, etc) are a fundamentally new class of cryptoeconomic organisms — decentralized, jurisdictionless entities that exist entirely in cyberspace, maintained by a combination of cryptography, economics and social consensus. They are kind of like BitTorrent, but they are also not like BitTorrent, as BitTorrent has no concept of state — a distinction that turns out to be crucially important. They are sometimes described as decentralized autonomous

1,300 E-JEEPNEY ORDER COMMITMENTS IN THE PHILIPPINES FOR TEMBO FRANCISCO MOTORS JOINT VENTURE

Source Node:
Time Stamp: January 18, 2024 1:50 PM - Modified On: January 18, 2024 - Published By:
Source Cluster:
Republished By Plato

Orders pursuant to Tembo’s previously announced joint venture with Francisco Motors Established in 1947, Francisco Motor Corporation is the original pioneering jeepney manufacturer Total addressable market to electrify 200,000 existing jeepneys estimated to be worth US$10bn+ Tembo E-LV, a subsidiary of the NASDAQ listed B Corp, VivoPower, announced today that, pursuant to its definitive joint venture agreement with Francisco Motor Corporation, it has been advised by Francisco Motors of a total of 1,300 order commitments received from several leading jeepney co-operatives in the Philippines, including Laguna, First Isabela, Progressive, and

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:09 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Zumo first to launch platform built to meet the tech requirements of the FCA’s new Financial Promotions Regime for Crypto Assets

Source Node:
Time Stamp: October 6, 2023 7:12 AM - Modified On: October 6, 2023 - Published By:
Source Cluster:
Republished By Plato

  The award-winning platform has set a new benchmark in consumer protection and regulatory alignment With some UK operators having to pause activity, Zumo’s financial promotions technical flow is now also available through its B2B API to support unregistered firms with remaining compliant after the 8 October deadline [London/Edinburgh - Friday 29 September 2023] Zumo, the UK-based digital-asset-as-a-service platform, has announced a significant industry milestone as it becomes the first digital asset platform to have integrated tech based requirements of the Financial Conduct Authority’s (FCA’s) new financial promotions regime for

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers